Eli Lilly announced a definitive agreement to acquire Ventyx Biosciences for $1.2 billion in cash. Lilly said the deal supplements its inflammation portfolio with Ventyx’s NLRP3 inhibitor assets, which Lilly expects could address chronic inflammatory drivers across cardiometabolic, neurodegenerative and autoimmune indications. Lilly framed the acquisition as strategic: Ventyx’s small‑molecule pipeline can be integrated into Lilly’s broader drug development capabilities to accelerate clinical programs. Company leaders highlighted the potential to advance best‑in‑class oral anti‑inflammatory candidates toward late‑stage trials.